This page uses content from Wikipedia and is licensed under CC BY-SA.

Pritumumab

Pritumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetvimentin
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6440H9968N1708O2016S42
Molar mass150 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Pritumumab is a human monoclonal antibody against vimentin[1] developed by Nascent Biotech. It is in clinical trials for the treatment of glioma.[2] The FDA granted orphan drug designation in 2015.

References